サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1634205

神経血管デバイスの世界市場 - 2025年～2033年

Global Neurovascular Devices Market - 2025 - 2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
神経血管デバイスの世界市場 - 2025年～2033年
出版日: 2025年01月13日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経血管デバイスの世界市場は、2023年に38億米ドルに達し、2033年には84億米ドルに達し、予測期間2025年～2033年にはCAGR 9.4%で成長すると予測されています。

神経血管デバイスは、脳や脊髄の血管に影響を及ぼす状態を治療するために設計された特殊な医療機器です。これらの器具は、主にインターベンショナル放射線学、神経学、神経外科学の一分野であるニューロインターベンションに関連する処置で使用され、様々な神経血管疾患の診断と治療のための低侵襲技術に焦点を当てています。

神経血管デバイスの主な目的は、低侵襲技術を用いて血流を回復させ、異常な血管を遮断または除去し、脳卒中、脳出血、動脈瘤などの生命を脅かす疾患を予防または治療することです。これらの機器は、回復時間や合併症を減らし、従来の開腹手術の必要性を減らすことで、患者の予後を改善することを目指しています。

神経血管デバイス市場は、神経血管障害の有病率の増加と神経血管デバイスの技術進歩により、大きな成長を遂げています。脳卒中、脳動脈瘤、動静脈奇形などの疾患は一般的になりつつあり、神経血管デバイスの需要を高めています。

例えば、世界脳卒中機構によると、毎年760万人以上の虚血性脳卒中が新たに発生しています。世界全体では、脳卒中発症の62％以上が虚血性脳卒中です。毎年、虚血性脳卒中全体の11％以上が15～49歳で発症しています。毎年、虚血性脳卒中全体の58％以上が70歳未満で発症しています。

さらに、2024年5月、ペナンブラ社は、急性虚血性脳卒中治療用の神経血管再灌流カテーテルRed 43、SendItテクノロジー搭載のRed 72、Red 78の3機種がCEマークを取得し、欧州で発売されることを発表しました。Penumbra社によると、これらのカテーテルは科学的根拠に基づく吸引血栓除去術（S-BAT）を最適化したもので、追跡可能性と吸引の最新技術により、広範囲の大血管閉塞に対応できるように設計されています。

市場力学：

促進要因と抑制要因

神経血管デバイスにおける技術進歩の高まり

神経血管デバイスの技術的進歩の高まりは、神経血管デバイス市場の成長を大きく後押ししており、予測期間中も市場を牽引していくと思われます。フローダイバータ、ステントリトリーバ、塞栓コイルなどの新しい神経血管デバイスは、侵襲性が低く、患者の回復時間や合併症を減らすように設計されています。例えば、2024年8月、グラビティ・メディカル・テクノロジー社は、次世代脳卒中治療デバイスであるニュートロン吸引カテーテルとSupernovaステントリトリーバーを発売しました。早期導入により、世界中で60人以上の患者の治療が成功しています。

このデバイスは、直径2～4.5mmの親血管から発生する頸部幅4mm以上またはドームと頸部の比が2以下の広頸部頭蓋内動脈瘤を治療するために、成人の神経血管塞栓用コイルとの併用に適応されます。

装置は現在、強化された2Dおよび3D画像技術と統合され、手技をガイドするためのリアルタイムの視覚化を提供します。この技術は、脳神経外科医がより正確にデバイスを配置し、より安全で効果的な治療を行うのに役立ちます。

例えば、ロイヤル・フィリップスは2024年2月、新しいAzurion neuro biplaneシステムの発売により、画像誘導治療システムAzurionの大幅な機能強化を発表しました。生産性を向上させ、医療チームがより迅速に適切な判断を下し、より多くの患者を治療し、より良い治療成績を達成できるように設計されたこの新しいインターベンションシステムは、2Dおよび3DイメージングとX線検出器の位置決めの柔軟性が強化されています。この新しい画像誘導治療システムは、脳卒中やその他の神経血管疾患患者の診断、画像誘導、治療評価を確実に行うための完全なインターベンショナル・ソリューションです。

代替治療の可能性

代替治療オプションの有無は、神経血管デバイス市場の成長を阻害する重要な要因の一つです。デバイスを用いた治療にはいくつかの代替手段が存在し、多くの場合、費用対効果、患者の嗜好、治療の低侵襲性などの要因により、これらの代替手段が好まれています。

虚血性脳卒中や脳動脈瘤のような神経血管障害の多くは、インターベンション機器ではなく薬物療法で治療できます。抗血小板薬（アスピリンなど）や抗凝固薬（ワルファリン、リバーロキサバンなど）のような薬理学的治療は、血栓形成を予防し、脳卒中や動脈瘤破裂のリスクを軽減することができます。例えば、急性虚血性脳卒中に対する血栓溶解薬（例えば、組織プラスミノーゲン活性化薬、tPA）の使用は、血栓除去術やその他の器具を用いた介入の必要性を減らすことができるため、神経血管デバイスの需要を制限することができます。

状況によっては、特に複雑で大きな動脈瘤や動静脈奇形（AVM）に対しては、従来の開腹手術が望ましい選択肢であり続けています。低侵襲手術に比べれば一般的ではないが、開腹手術はより確立された信頼性の高い選択肢です。例えば、大きな脳動脈瘤や治療が困難な脳動脈瘤の患者には、塞栓術や流路転換術よりもクリッピング手術が推奨されることがあり、神経血管デバイスの市場シェアを低下させる可能性があります。

脳腫瘍、動静脈奇形、その他の血管病変の治療には、定位放射線手術やレーザーアブレーションなどの代替治療が好まれることがあります。これらの方法は、従来の神経血管手術よりもリスクが少なく、侵襲性も低いです。例えば、ガンマナイフによる放射線手術は、AVMに対する塞栓術や外科的切除術の代替として、特に小さな病変に対して頻繁に用いられています。

目次

第1章 市場イントロダクションと範囲

  • 報告書の目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • 製品タイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 神経血管デバイスにおける技術の進歩
    • 抑制要因
      • 代替品の入手可能性
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名な企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 神経血管デバイス市場、製品タイプ別

  • 脳塞栓術および動脈瘤コイル塞栓術
    • 塞栓コイル
    • 流れ転換装置
    • 液体塞栓剤
  • 脳血管形成術およびステント留置システム
    • 頸動脈ステント
    • 塞栓保護システム
  • 神経血栓除去装置
    • 血栓除去装置
    • 吸引装置/吸引カテーテル
    • 血管スネア
  • サポートデバイス
    • マイクロカテーテル
    • マイクロガイドワイヤー
  • トランスラジアルアクセスデバイス

第6章 神経血管デバイス市場、用途別

  • 脳動脈瘤
  • 虚血性脳卒中
  • 頸動脈狭窄症
  • その他

第7章 神経血管デバイス市場、エンドユーザー別

  • 病院
  • 専門クリニック
  • 外科センター
  • 調査室および学術機関
  • 外来手術センター

第8章 神経血管デバイス市場、地域別、市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Medtronic plc
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Stryker Corporation
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • Johnson & Johnson
  • Penumbra, Inc.
  • ASAHI INTECC USA, INC.
  • Acandis GmbH
  • Rapid Medical
  • NeuroVasc Technologies, Inc.

第11章 仮定と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証と検証

第12章 付録

目次
Product Code: MD2674

The global neurovascular devices market reached US$ 3.8 billion in 2023 and is expected to reach US$ 8.4 billion by 2033, growing at a CAGR of 9.4% during the forecast period 2025-2033.

Neurovascular devices are specialized medical instruments designed to treat conditions affecting the blood vessels of the brain and spinal cord. These devices are primarily used in procedures related to neurointervention, a branch of interventional radiology, neurology and neurosurgery, which focuses on minimally invasive techniques for diagnosing and treating various neurovascular diseases.

The main purpose of neurovascular devices is to restore blood flow, block or remove abnormal blood vessels, and prevent or treat life-threatening conditions like strokes, brain hemorrhages and aneurysms, using minimally invasive techniques. These devices aim to improve patient outcomes by reducing recovery time, complications, and the need for traditional open surgeries.

The neurovascular devices market is experiencing significant growth, driven by the increasing prevalence of neurovascular disorders and technological advancements in neurovascular devices. Conditions such as stroke, cerebral aneurysms, and arteriovenous malformations are becoming more common, increasing the demand for neurovascular devices.

For instance, according to the World Stroke Organization, there are over 7.6 million new ischaemic strokes each year. Globally, over 62% of all incident strokes are ischaemic strokes. Each year, over 11% of all ischaemic strokes occur in people 15-49 years of age. Each year, over 58% of all ischaemic strokes occur in people under 70 years of age.

Additionally, in May 2024, Penumbra, Inc. announced the CE Mark approval and the launch in Europe of three of its neurovascular reperfusion catheters Red 43, Red 72 with SendIt technology, and Red 78 for the treatment of acute ischemic stroke. According to Penumbra, the devices optimize science-based aspiration thrombectomy, or S-BAT, and are engineered with the latest technology in trackability and aspiration to address a wide range of large vessel occlusions.

Market Dynamics: Drivers & Restraints

Rising technological advancements in neurovascular devices

The rising technological advancements in neurovascular devices are significantly driving the growth of the neurovascular devices market and are expected to drive the market over the forecast period. Newer neurovascular devices, such as flow diverters, stent retrievers and embolic coils, are designed to be less invasive, reducing recovery times and complications for patients. For instance, in August 2024, Gravity Medical Technology launched its next-generation stroke treatment devices: the Neutron aspiration catheter and the Supernova stent retriever. Early adoption has demonstrated the successful treatment of more than 60 patients worldwide.

Additionally, in June 2024, Terumo subsidiary MicroVention launched its LVIS EVO intraluminal support device to treat wide neck intracranial aneurysms in the U.S. The device is indicated for usage with neurovascular embolization coils in adults to treat saccular intracranial aneurysms with a neck width of 4 mm or greater or a dome-to-neck ratio of less than two that arise from a parent vessel with a diameter between 2 and 4.5 mm.

Devices now integrate with enhanced 2D and 3D imaging technologies, providing real-time visualization to guide procedures. This technology helps neurosurgeons place devices more precisely, ensuring safer and more effective treatments.

For instance, in February 2024, Royal Philips announced major enhancements to its Image Guided Therapy System, Azurion, with the launch of its new Azurion neuro biplane system. Designed to improve productivity and help care teams make the right decisions faster, treat more patients, and achieve better outcomes, the new interventional system features enhanced 2D and 3D imaging and X-ray detector positioning flexibility. The new image-guided therapy system is a complete interventional solution for confident diagnosis, image guidance, and therapy assessment of patients with stroke or other neurovascular diseases

Availability of alternatives

The availability of alternative treatment options is one of the key factors that can hamper the growth of the neurovascular devices market. Several alternatives to device-based interventions exist, and in many cases, these alternatives are preferred due to factors such as cost-effectiveness, patient preference and the less invasive nature of the treatments.

Many neurovascular disorders, such as ischemic stroke or cerebral aneurysms, can be treated using medications rather than interventional devices. Pharmacological treatments like antiplatelet drugs (e.g., aspirin) and anticoagulants (e.g., warfarin, rivaroxaban) can prevent clot formation and reduce the risk of stroke or aneurysm rupture. For instance, the use of thrombolytics (e.g., tissue plasminogen activator, tPA) for acute ischemic stroke can often reduce the need for thrombectomy or other device-based interventions, thus limiting demand for neurovascular devices.

In some situations, traditional open surgery remains the preferred option, especially for complex or large aneurysms and arteriovenous malformations (AVMs). Although less commonly used than minimally invasive methods, open surgery can be seen as a more established and reliable option. For instance, for patients with large or difficult-to-treat brain aneurysms, clipping surgery may be recommended over embolization or flow diversion, which can reduce the market share of neurovascular devices.

Alternatives like stereotactic radiosurgery or laser ablation are sometimes preferred for treating brain tumors, arteriovenous malformations, and other vascular lesions. These methods can offer less risk and are less invasive than traditional neurovascular procedures. For instance, Gamma Knife radiosurgery is frequently used as an alternative to embolization or surgical resection for AVMs, particularly for small lesions.

Segment Analysis

The global neurovascular devices market is segmented based on product type, application, end-user and region.

Product Type:

The cerebral angioplasty and stenting systems segment is expected to dominate the neurovascular devices market share

Over the years, technological advancements in angioplasty and stenting systems have improved treatment efficacy, safety and patient outcomes. The development of self-expanding stents, drug-eluting stents and balloon angioplasty systems has enhanced the precision and success rates of neurovascular procedures.

For instance, in June 2023, Fluid Biomed Inc. announced the World's first implantation of a polymer-based neurovascular stent in human patients, REDIRECT, its first-in-human clinical trial. Phase 1 of this technical feasibility and safety study has begun with successful device implantation without adverse effects in human subjects at the pre-determined 30-day time point and recruitment is ongoing.

Cerebral angioplasty and stenting are minimally invasive procedures, which are preferred by both patients and physicians because they involve smaller incisions, reduced recovery times, and fewer complications compared to traditional open surgeries. For instance, Angioplasty with stenting for carotid artery disease is performed through a small incision in the groin, making it a less traumatic alternative to surgery. This less invasive nature drives higher adoption of stenting systems in treating neurovascular diseases.

Endovascular treatments, such as cerebral angioplasty and stenting, are increasingly becoming the first line of treatment for neurovascular disorders due to their effectiveness and reduced risks compared to open surgery. This shift in preference is contributing to the dominance of the segment.

Geographical Analysis

North America is expected to hold a significant position in the neurovascular devices market share

North America especially the United States, is a hub for innovation in medical devices, with leading companies such as Medtronic, Stryker Corporation, Terumo Corporation and other leading players developing new and improved neurovascular devices. This includes the development of stent retrievers, flow diverters and clot removal devices that are highly effective in treating stroke and aneurysms.

For instance, in February 2024, CERENOVUS, Inc., part of Johnson & Johnson MedTech, launched CEREGLIDE 71 Intermediate Catheter, a next-generation intermediate catheter with TruCourse indicated for the revascularization of patients suffering from acute ischemic stroke. CEREGLIDE 71 Intermediate Catheter is the latest innovation in a planned CEREGLIDE Family of Catheters to join the CERENOVUS STROKE SOLUTIONS portfolio and is optimized for effective direct aspiration and for the delivery of compatible stent retrievers, including the EMBOTRAP III Revascularization Device, into the neurovasculature.

Asia-Pacific is growing at the fastest pace in the neurovascular devices market

The Asia Pacific region has a growing incidence of stroke, aneurysms, and carotid artery diseases due to lifestyle factors, rising levels of hypertension, smoking, and diabetes, which are risk factors for neurovascular conditions. For instance, the World Health Organization (WHO) reports that Asia, particularly China and India, has a high incidence of ischemic stroke, with nearly 70% of all strokes occurring in low- and middle-income countries in Asia. This significantly boosts the demand for neurovascular devices such as stents, coils, and thrombectomy systems.

There is an increasing awareness of minimally invasive neurovascular procedures such as stenting, angioplasty, and thrombectomy in the Asia Pacific region. As healthcare professionals and patients become more informed about the benefits of these procedures, the demand for neurovascular devices increases. For instance, the use of thrombectomy systems like the Solitaire FR Stent Retriever is growing in countries like India and China as part of the initiative to improve stroke treatment outcomes.

Competitive Landscape

The major global players in the neurovascular devices market include Medtronic plc, Stryker Corporation, Terumo Corporation, MicroPort Scientific Corporation, Johnson & Johnson, Penumbra, Inc., ASAHI INTECC USA, INC., Acandis GmbH, Rapid Medical, NeuroVasc Technologies, Inc. and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global neurovascular devices market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements in Neurovascular Devices
    • 3.1.2. Restraints
      • 3.1.2.1. Availability of Alternatives
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Neurovascular Devices Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Cerebral Embolization and Aneurysm Coiling Devices*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Embolic Coils
    • 5.2.4. Flow Diversion Devices
    • 5.2.5. Liquid Embolic Agents
  • 5.3. Cerebral Angioplasty and Stenting Systems
    • 5.3.1. Carotid Artery Stents
    • 5.3.2. Embolic Protection Systems
  • 5.4. Neurothrombectomy Devices
    • 5.4.1. Clot Retrieval Devices
    • 5.4.2. Suction Devices/Aspiration Catheters
    • 5.4.3. Vascular Snares
  • 5.5. Support Devices
    • 5.5.1. Micro Catheters
    • 5.5.2. Micro Guidewires
  • 5.6. Trans Radial Access Devices

6. Neurovascular Devices Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Cerebral Aneurysms*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Ischemic Stroke
  • 6.4. Carotid Artery Stenosis
  • 6.5. Others

7. Neurovascular Devices Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Surgical Centers
  • 7.5. Research Laboratories and Academic Institutes
  • 7.6. Ambulatory Surgical Centers

8. Neurovascular Devices Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Medtronic plc*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Stryker Corporation
  • 10.3. Terumo Corporation
  • 10.4. MicroPort Scientific Corporation
  • 10.5. Johnson & Johnson
  • 10.6. Penumbra, Inc.
  • 10.7. ASAHI INTECC USA, INC.
  • 10.8. Acandis GmbH
  • 10.9. Rapid Medical
  • 10.10. NeuroVasc Technologies, Inc.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us